Introduction：Basic information about CAS 946414-94-4|Nivolumab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Nivolumab |
|---|
| CAS Number | 946414-94-4 | Molecular Weight | / |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | / | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
Nivolumab BiologicalActivity
| Description | Nivolumab (anti-PD-1) is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer[1]. |
|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Immunology/Inflammation >>PD-1/PD-L1 |
|---|
| In Vitro | Nivolumab (anti-PD-1) binds to CHO cells expressing PD-1 with an EC50 of 1.66 nM, but does not bind to the parental CHO cell line. Nivolumab (anti-PD-1) binds to PD-1 on activated T cells with an EC50 of 0.64 nM. Nivolumab (anti-PD-1) also inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with IC50 values of 2.52 and 2.59 nM, respectively. Nivolumab (anti-PD-1) (1.5 ng/mL) can enhance T-cell reactivity in the presence of a T-cell receptor stimulus[1]. |
|---|
| In Vivo | Nivolumab (anti-PD-1) (10 and 50 mg/kg, i.v.) is well tolerated in cynomolgus monkeys. Serum chemistry changes are limited to a reversible 28% decrease in T3 at week 13 in females treated with 50 mg/kg. T4 and TSH levels are unchanged. In males treated with 50 mg/kg, there are no changes in T3, T4, or TSH levels. Nivolumab (anti-PD-1) exposure increases in an approximately dose-proportional manner between 10 and 50 mg/kg, with no substantial sex differences noted[1]. |
|---|
| References | [1]. Wang C, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014 Sep;2(9):846-56. |
|---|
Chemical & Physical Properties
| InChIKey | VSTHRBNUEGPUOM-UHFFFAOYSA-N |
|---|
| SMILES | CC(C=CS(C)(=O)=O)CC(=O)c1cccc2c1NC(C)(C)CC2C.CC1=CC(C)(C)Nc2c(C(=O)CC(C)C=CS(C)(=O)=O)cccc21.CC1=CC(C)(C)Nc2c(C(=O)CCC=CS(C)(=O)=O)cccc21.CC1CC(C)(C)Nc2c(C(=O)CCC=CS(C)(=O)=O)cccc21 |
|---|
